IMR Press / FBL / Volume 9 / Issue 3 / DOI: 10.2741/1388

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Alterations of cell signaling pathways in pancreatic cancer
Show Less
1 Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229
2 Research and Development, Audie Murphy Veterans Administration Hospital, San Antonio, TX 78229
Academic Editor:Subhas Chakrabarty
Front. Biosci. (Landmark Ed) 2004, 9(3), 1889–1898;
Published: 1 May 2004
(This article belongs to the Special Issue Selected topics in cancer research:current advances)

Pancreatic ductal adenocarcinomas continue to have the worst prognosis of any adult malignancy with a five-year survival rate of less than 4%. One approach to improve patient survival from pancreatic cancer is to identify new biological targets that contribute to the aggressive pathogenecity of this disease and to develop reagents that will interfere with the function of these targets. Apart from the identification of the genetic profile of pancreatic cancer, a number of studies have focused on aberrant cell signaling pathways and their role in pancreatic cancer biology and response to therapy. This review, although not comprehensive, will discuss the salient features of several of these pathways. These include the roles of TGFβ signaling in both tumor suppression and tumor promotion and the effects of deregulation of phosphotyrosine kinase receptor signaling pathways in pancreatic cancer.

Pancreatic cancer
Cell signaling
Growth factors
Growth factor receptors
Back to top